Skip to Content

Women exposed to DES in the womb face increased cancer risk

NIH study followed daughters of women given diethylstilbestrol during pregnancy and found increased fertility problems and cancer risks

Posted on October 05, 2011

A large study of the daughters of women who had been given DES, the first synthetic form of estrogen, during pregnancy has found that exposure to the drug while in the womb (in utero) is associated with many reproductive problems and an increased risk of certain cancers and pre-cancerous conditions. The results of this analysis, conducted by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and collaborators across the country, were published Oct. 6, 2011, in the New England Journal of Medicine.

News Sources

NCI Press Release: Women exposed to DES in the womb face increased cancer risk

The National Cancer Institute (NCI) press release for the study  

NCI Cancer Bulletin: After DES: Tracking the harms of a prenatal drug exposure

News article in NCI’s bi-weekly newsletter the Cancer Bulletin

NCI Cancer Bulletin: The DES story: Lessons learned

Video highlight in NCI’s bi-weekly newsletter the Cancer Bulletin

DCEG Linkage: The DES Follow-Up Study

Feature article in the DCEG Linkage Newsletter

Information for Journalists

To request an interview with a DCEG investigator, contact the NCI Office of Media Relations:

E-mail:
ncipressofficers@mail.nih.gov

Phone: 301-496-6641